Availability of Opportunity to Provide Input for the National Occupational Research Agenda, 36611-36612 [05-12500]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 121 / Friday, June 24, 2005 / Notices
inadequate for widespread use in
preventive medicine and public health.
As part of the family history initiative,
CDC is developing an electronic, selfadministered, Web-based tool that
assesses familial risk for six diseases
and recommends early detection and
prevention strategies. The tool collects:
• Name, date of birth, gender,
adoption status, Ashkenazi Jewish
heritage.
• Current height and weight.
• Health behaviors: smoking, physical
activity, fruit and vegetable
consumption, alcohol use, aspirin use.
• Screening tests: clinical breast
exam, mammogram, fecal occult blood
test, sigmoidoscopy, colonoscopy, blood
cholesterol, blood pressure, and blood
sugar.
• Disease history of a person’s firstand second-degree relatives (mother,
father, grandparents, siblings, aunts and
uncles) for coronary heart disease,
stroke, diabetes, and colorectal, breast,
and ovarian cancer.
Algorithms in the software analyze
the data and assess risk based on the
number of relatives affected, their age at
disease onset, their gender, the
closeness of the relatives to each other
and the user, and the combinations of
diseases in the family. The tool provides
the user with a report that includes an
assessment of familial risk for each
disease (described as strong, moderate
or weak), an explanation as to why the
family history is a risk factor, and
recommendations for disease prevention
and screening that are targeted to the
familial risk and based on answers to
the health behavior and screening
questions. An evaluation trial of Family
HealthwareTM; set in primary practice
clinics will begin in July 2005.
Inventors: Maren T. Scheuner, Paula
W. Yoon, Muin J. Khoury, and Cynthia
Jorgensen.
CDC Ref. #: I–004–04.
Dated: June 13, 2005.
James D. Seligman,
Associate Director for Program, Services,
Centers for Disease Control and Prevention.
[FR Doc. 05–12498 Filed 6–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Health
Promotion and Diabetes Prevention
Projects for American Indian/Alaska
Native Communities: Adaptations of
Practical Community Environmental
Indicators, Program Announcement
Number AA029
Availability of Opportunity to Provide
Input for the National Occupational
Research Agenda
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Health Promotion and Diabetes
Prevention Projects for American Indian/
Alaska Native Communities: Adaptations of
Practical Community Environmental
Indicators, Program Announcement Number
AA029.
Times and Dates: 9 a.m.–5 p.m., August 2,
2005 (Closed); 9 a.m.–5 p.m., August 3, 2005
(Closed); 9 a.m.–4 p.m., August 4, 2005
(Closed).
Place: Club House Inn and Suites, 1315
Menaul Boulevard NE., Albuquerque, NM
87107, Telephone Number (505) 345–0010.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to: Health Promotion and Diabetes
Prevention Projects for American Indian/
Alaska Native Communities: Adaptations of
Practical Community Environmental
Indicators, Program Announcement Number
AA029.
For Further Information Contact: Maria E.
Burns, M.P.A., Senior Program Management
Officer, National Center for Chronic Disease
Prevention and Health Promotion, CDC, 1720
Louisiana Boulevard, NE., Albuquerque, NM
87110, Telephone (505) 232–9907.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: June 20, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–12499 Filed 6–23–05; 8:45 am]
BILLING CODE 4163–18–P
VerDate jul<14>2003
19:06 Jun 23, 2005
Jkt 205001
36611
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the following:
Availability of Opportunity for the
Public to Provide Input for the National
Occupational Research Agenda (NORA).
For the past nine years, NORA has
served as a framework to guide
occupational safety and health research
in the nation. Approximately 500
participants outside NIOSH provided
input into the development of the first
agenda. Building on the success of
NORA, the second decade of NORA will
use a sector-based approach.
NIOSH and its partners under NORA
are pleased to introduce a newly
updated NORA Web site at https://
www.cdc.gov/niosh/nora. An important
feature of the updated page is an online
feedback form. We hope both
individuals and organizations will use
this opportunity to submit comments
and suggestions for guiding the design
of future occupational safety and health
research in the nation.
The Web site allows stakeholders to
describe what they perceive to be the
top research needs within each sector,
sub-sector, or in multiple sectors.
Stakeholders can submit comments on
the approach to redesigning NORA as it
enters its second decade. We invite
partners and collaborators to use the
electronic option to provide comments,
which will automatically be entered
into the NORA Docket maintained by
NIOSH.
Experience gained in the first decade
of NORA indicates that the following
types of information may help identify
the areas where new research will make
the greatest contributions to preventing
work-related injuries, illnesses, and
deaths:
• Number of workers at risk
• Seriousness of the hazard
• Probability that new information
and approaches will make a difference
Alternatively, comments may be emailed to NIOCINDOCKET@cdc.gov or
mailed to: Docket NIOSH–047, Robert
A. Taft Laboratories (C–34), 4676
Columbia Parkway, Cincinnati, OH
45226.
The public may also view the
complete NORA Docket at this location.
E:\FR\FM\24JNN1.SGM
24JNN1
36612
Federal Register / Vol. 70, No. 121 / Friday, June 24, 2005 / Notices
Contact for Additional Information:
noracoordinator@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: June 17, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–12500 Filed 6–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Infectious Particle Composition and
Methods of Use Thereof
Chava Kimchi-Sarfaty and Michael M.
Gottesman (NCI),
DHHS Reference No. E–138–2005/0–
US–01.
Licensing Contact: Michelle A. Booden;
(301) 451–7337;
boodenm@mail.nih.gov.
Current methods for delivery of small
interfering RNA (siRNA) and short
hairpin RNA (shRNA) such as cationic
VerDate jul<14>2003
19:06 Jun 23, 2005
Jkt 205001
lipid or polyplex delivery systems, do
not efficiently deliver siRNAs or
shRNAs into a wide range of cell types.
Subsequent innovations have resulted
in shRNA, but not siRNA, expression
cassettes that have been adapted to be
compatible with most DNA-based viral
vector systems including retroviruses,
adenoviruses, lentiviruses, and adenoassociated viruses. As with the transfer
of cDNAs, all of these delivery systems
require a significant degree of
optimization and are often only useful
in specific cell systems. Additionally,
some viral vectors also have the
disadvantage of low titer and large
genome size. Further, some of the above
viral delivery systems are dependent on
helper viruses or packaging cell lines,
and some are not able to transduce nondividing cells, or cells in suspension.
Also inherent in current DNA viral
delivery systems is a lack of efficiency
in delivering the DNA or RNA of
interest to the nucleus. Instead, the DNA
vector and concomitant siRNA insert
remains in the cytoplasm.
siRNA is emerging as a powerful tool
for gene silencing and has much
potential for anticancer and antiviral
applications. However, efficient
delivery of these specific siRNAs to the
nucleus of a cell is an important aspect
of interfering with specific DNA
transcription. The present invention
provides compositions and methods for
use of infectious particles, such as
papovavirus pseudovirions, to deliver
siRNAs into a variety of mammalian
cells. More specifically, the infectious
particles may comprise the SV40 capsid
protein VP1, papilloma virus capsid
protein L1, polyoma virus capsid
protein VP1, or several SV40 capsid
proteins. The claims further comprise
methods for in vivo transfer of siRNA as
well as a kit comprising the infectious
particle and instructions for use as a
siRNA delivery system. This
pseudovirions technology has proved to
be an excellent alternative to DNA-viral
vectors for siRNA delivery with high
capacity, very high efficiency, and no
viral DNA complications. The
pseudovirion delivery technology is
described in the following background
publications: Kimchi-Sarfaty et al.,
Human Gene Therapy 13: 299–310,
2002; Kimchi-Sarfaty et al., Human
Gene Therapy 14: 167–177, 2003; and
Kimchi-Sarfaty et al., Gene Ther Mol
Biol 8: 439–450, 2004.
This technology is available for
licensing on an exclusive or a nonexclusive basis. In addition to licensing,
the technology is available for further
development through collaborative
research opportunities with the
inventors.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Polyclonal Antibodies to Human
Thyroid Hormone Beta Receptor, JC8TRb1 And JC16–TRb1
Dr. Sheue-yann Cheng,
DHHS Reference No. E–153–2003/0—
Research Tool.
Licensing Contact: Marlene Shinn-Astor;
(301) 435–4426;
shinnm@mail.nih.gov.
In human tissues, there are five
thyroid hormone receptor subtypes,
TRb1, TRb2, TRb3, TRa1, and TRa2.
High affinity polyclonal and
monoclonal antibodies have been
developed to specifically recognize TRb
and TRa1 in human and mouse tissues.
These antibodies have been designated
as JC8–TRb1 and JC16–TRb1. These
antibodies could be used by researchers
worldwide in both clinical and research
applications.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Dated: June 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–12597 Filed 6–23–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–339]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
AGENCY:
E:\FR\FM\24JNN1.SGM
24JNN1
]]>Agencies
[Federal Register Volume 70, Number 121 (Friday, June 24, 2005)]
[Notices]
[Pages 36611-36612]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12500]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Availability of Opportunity to Provide Input for the National
Occupational Research Agenda
The National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC) announces the
following:
Availability of Opportunity for the Public to Provide Input for the
National Occupational Research Agenda (NORA).
For the past nine years, NORA has served as a framework to guide
occupational safety and health research in the nation. Approximately
500 participants outside NIOSH provided input into the development of
the first agenda. Building on the success of NORA, the second decade of
NORA will use a sector-based approach.
NIOSH and its partners under NORA are pleased to introduce a newly
updated NORA Web site at https://www.cdc.gov/niosh/nora. An important
feature of the updated page is an online feedback form. We hope both
individuals and organizations will use this opportunity to submit
comments and suggestions for guiding the design of future occupational
safety and health research in the nation.
The Web site allows stakeholders to describe what they perceive to
be the top research needs within each sector, sub-sector, or in
multiple sectors. Stakeholders can submit comments on the approach to
redesigning NORA as it enters its second decade. We invite partners and
collaborators to use the electronic option to provide comments, which
will automatically be entered into the NORA Docket maintained by NIOSH.
Experience gained in the first decade of NORA indicates that the
following types of information may help identify the areas where new
research will make the greatest contributions to preventing work-
related injuries, illnesses, and deaths:
Number of workers at risk
Seriousness of the hazard
Probability that new information and approaches will make
a difference
Alternatively, comments may be e-mailed to NIOCINDOCKET@cdc.gov or
mailed to: Docket NIOSH-047, Robert A. Taft Laboratories (C-34), 4676
Columbia Parkway, Cincinnati, OH 45226.
The public may also view the complete NORA Docket at this location.
[[Page 36612]]
Contact for Additional Information: noracoordinator@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: June 17, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-12500 Filed 6-23-05; 8:45 am]
BILLING CODE 4163-18-P
